{"id":391486,"date":"2014-12-04T00:00:00","date_gmt":"2014-12-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorcg0614-biopharma-unipolar-depression-pharmacor-g7-2014\/"},"modified":"2026-03-31T09:04:20","modified_gmt":"2026-03-31T09:04:20","slug":"pcorcg0614-biopharma-unipolar-depression-pharmacor-g7-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pcorcg0614-biopharma-unipolar-depression-pharmacor-g7-2014\/","title":{"rendered":"Unipolar Depression | Pharmacor | G7 | 2014"},"content":{"rendered":"<p><em>Last Updated 4 December 2014<\/em><br \/>\nUnipolar depression\u2014comprising major depressive disorder (MDD), minor depression, and dysthymia\u2014is a highly prevalent psychiatric disorder affecting nearly 85 million individuals in the seven major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Throughout our 2013-2023 study period, the unipolar depression therapy market will consist almost entirely of generic products that dominate treatment, particularly in the early lines. Only a few branded products\u2014namely Forest Laboratories\u2019 (now a subsidiary of Actavis) vilazodone (Viibryd), Lundbeck\/Takeda Pharmaceutical\u2019s vortioxetine (Brintellix), Forest Laboratories (now a subsidiary of Actavis)\/Pierre Fabre\u2019s levomilnacipran (Fetzima), Otsuka Pharmaceutical\/Lundbeck\u2019s brexpiprazole, Forest Laboratories (now a subsidiary of Actavis)\/Gedeon Richter\/Mitsubishi Tanabe Pharma\u2019s cariprazine, and Sumitomo Dainippon\/Sunovion\/Takeda Pharmaceutical\u2019s lurasidone (Latuda)\u2014will be competing for market share during the forecast period in this highly genericized space. Although the age of blockbuster antidepressants is largely a thing of the past, low patient response rates and even lower remission rates following treatment with first-line therapies leave opportunity for adjunctive agents for MDD and for monotherapies targeting specific patient subpopulations, particularly those with treatment-resistant depression (TRD) or residual symptoms of depression.<\/p>\n","protected":false},"template":"","class_list":["post-391486","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-unipolar-depression","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391486\/revisions"}],"predecessor-version":[{"id":394609,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391486\/revisions\/394609"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}